UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2023 P 1318-4
Program	Prior Authorization/Notification
Medication	Isturisa® (osilodrostat)
P&T Approval Date	6/2020, 6/2021, 6/2022, 6/2023
Effective Date	9/1/2023; Oxford only: 9/1/2023

1. **Background:**
   Isturisa (osilodrostat) is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

2. **Coverage Criteria[a]:**

A. <u>Initial Authorization</u>

1. **Isturisa** will be approved based on **<u>both</u>** of the following criteria:

   a. Diagnosis of Cushing's disease

   -AND-

   b. **<u>One</u>** of the following:

   (1) Patient is not a candidate for pituitary surgery

   -OR-

   (2) Pituitary surgery has not been curative

   Authorization will be issued for 12 months.

B. <u>Reauthorization</u>

1. **Isturisa** will be approved based on the following criterion:

   a. Documentation of positive response to Isturisa therapy

   Authorization will be issued for 12 months.

[a] State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

© 2023 UnitedHealthcare Services, Inc.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply Limits may be in place

4. References:

1. Isturisa [Package Insert]. Lebanon, NJ: Recordati Rare Disease, Inc.; March 2020.

Program	Prior Authorization/Notification - Isturisa (osilodrostat)
Change Control	
6/2020	New program
6/2021	Annual review with no change to coverage criteria.
6/2022	Annual review with no change to clinical criteria.
6/2023	Annual review with no change to coverage criteria. Added state mandate footnote.

© 2023 UnitedHealthcare Services, Inc.